The European Union has officially launched the Partnership on One Health Antimicrobial Resistance (OHAMR). Co-funded by Horizon Europe with €75 million, this ambitious 10-year programme tackles the urgent global health threat of antimicrobial resistance (AMR).
Next steps
AMR causes over 35,000 deaths annually in the EU and 1.27 million worldwide (2019), with projections of up to 10 million per year by 2050. It occurs when microbes like bacteria or viruses become resistant to treatments, driven by antimicrobial misuse, poor infection control, and limited diagnostics. AMR is a threat to modern medicine that strains health systems as well as economies.
Coordinated by the Swedish Research Council, OHAMR brings together 53 organisations from 30 countries, and it uses a One Health approach to connect sectors and accelerate solutions reducing antimicrobial use and resistance. Activities planned under the partnership include:
- Joint transnational calls for collaborative research and innovation projects;
- Strengthening research capacity in participating countries;
- Promoting the translation of knowledge into practice and policy;
- Supporting access to and better use of data on AMR;
- Increasing impact through coordination and alignment of national and European efforts.
More Information
Research and innovation on antimicrobial resistance (AMR)
Source: European Commission | Research and Innovation | News | All research and innovation news (https://tinyurl.com/mpbuze3v)